| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/07/2005 | US20050074446 Gamma-tocopherol treatment for cystic fibrosis |
| 04/07/2005 | US20050074445 Alpha-tocopherol treatment for cystic fibrosis |
| 04/07/2005 | US20050074444 Nutritional supplement; aqueous emulsion containing coenzyme Q10 and solubilizer; preferably also including vitamin E, betacarotene, vitamin D and vitamin K; immunostimulation; reducing oxidative stress and respiratory complications |
| 04/07/2005 | US20050074443 Fatty alcohol combined with vitamin B12, vitamin D, coenzyme Q and/or omega-3 fatty acid; decreasing tissue destructive inflammation; nontoxic |
| 04/07/2005 | US20050074442 Compositions and methods for augmenting kidney function |
| 04/07/2005 | US20050074436 Systems and methods for treating patients with processed lipoaspirate cells |
| 04/07/2005 | US20050074429 Optimal compositions and methods thereof for treating HCV infections |
| 04/07/2005 | US20050074427 IL-17 like molecules and uses thereof |
| 04/07/2005 | US20050074426 A conjugate of a cytokine and a tumor targeting moiety with numerous provisos |
| 04/07/2005 | US20050074425 Method for delivering polymerized therapeutic agent compositions and compositions thereof |
| 04/07/2005 | US20050074424 Using polyion polymers with glucose infusion for a cancer selective chemotherapy compound and method |
| 04/07/2005 | US20050074414 Penetrating pharmaceutical foam |
| 04/07/2005 | US20050074412 especially for endoscopic surgery, comprising a rinsing fluid and nitrous oxide added as a marker in an amount detectable in the expired breath from a mammal, especially man, that is subjected to the surgery. |
| 04/07/2005 | US20050074408 Compounds for fluorescent emission for animals |
| 04/07/2005 | DE19912850B4 Lösung, insbesondere für Hämo- oder Peritonealdialyse, sowie Verfahren zu deren Herstellung Solution, in particular for hemodialysis or peritoneal dialysis, as well as processes for their preparation |
| 04/07/2005 | DE19845402B4 Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung -Containing heterocycles substituted with Propanolaminderivate, process for their production, medicaments containing these compounds and their use |
| 04/07/2005 | DE10360869A1 Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma Use of fumaric acid derivatives for the treatment of heart failure, hyperkeratosis and asthma |
| 04/07/2005 | DE10346083A1 Pulverförmige Zusammensetzung zur Verwendung als Laxativum Pulverulent composition for use as a laxative |
| 04/07/2005 | DE10342212A1 Verwendung von Licocalchon A oder eines Licocalchon A enthaltenden Extraktes aus Radix Glycyrrhizae inflatae gegen Hautalterung Use of licochalcone A or A licochalcone containing extract of Radix Glycyrrhizae inflatae against skin aging |
| 04/07/2005 | DE10341923A1 Verwendung von Tolperison Use of Tolperisone |
| 04/07/2005 | DE10341240A1 Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament Substituted Thienoimidazole, processes for their preparation, their use as a medicament or diagnostic, and they drug-containing |
| 04/07/2005 | DE10340829A1 Salzarme oder salzfreie mikrobizide Zusammensetzung auf Basis von Isothiazolon-Derivaten und Pyriondisulfid Low-salt or salt-free microbicidal composition based on isothiazolone derivatives and pyrione disulphide |
| 04/07/2005 | DE10340747A1 Use of a 11-beta-hydroxysteroid oxidoreductase inhibitor or cortisol synthesis activator to prepare a topical pharmaceutical or cosmetic composition for stimulating breast growth |
| 04/07/2005 | DE10339354A1 Synergistic composition for treating metabolic syndrome, comprises swellable or gel-forming satiating and weight reducing agent and hypocholesterolemic and/or antidiabetic agent |
| 04/07/2005 | CA2814269A1 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| 04/07/2005 | CA2744997A1 C-met modulators and method of use |
| 04/07/2005 | CA2581996A1 Buccal, polar and non-polar spray containing alprazolam |
| 04/07/2005 | CA2580733A1 (-)-hydroxycitric acid for delaying gastric emptying |
| 04/07/2005 | CA2580730A1 Tetrahydroindolone derivatives for treatment of neurological conditions |
| 04/07/2005 | CA2554982A1 Method of inhibiting remnant lipoprotein production |
| 04/07/2005 | CA2540827A1 Methods of [11c]-radiolabelling phenothiazine and phenothiazine-like compounds |
| 04/07/2005 | CA2540701A1 Proteins expressed in nk cells |
| 04/07/2005 | CA2540518A1 Compounds and compositions as protein kinase inhibitors |
| 04/07/2005 | CA2540488A1 Pharmaceutical formulation with improved stability |
| 04/07/2005 | CA2540364A1 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers |
| 04/07/2005 | CA2540355A1 Phenylene derivative having tetrazole ring or thiazolidinedione ring |
| 04/07/2005 | CA2540325A1 Methods for treating bladder dysfunction |
| 04/07/2005 | CA2540243A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors |
| 04/07/2005 | CA2540242A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors |
| 04/07/2005 | CA2540239A1 Imidazo(4,5-b)pyridine-derivatives as inducible no-synthase inhibitors |
| 04/07/2005 | CA2540208A1 Amino acids with affinity for the alpha2delta-protein |
| 04/07/2005 | CA2540197A1 Treatment of neurological disorders related to rapid eye movement (rem) sleep disturbances with npy y5 receptor antagonists |
| 04/07/2005 | CA2540190A1 Use of npy y5 receptor antagonist for the treatment of circadian rhythm disorders |
| 04/07/2005 | CA2540186A1 Phenyl-piperazine derivatives as modulators of muscarinic receptors |
| 04/07/2005 | CA2540160A1 Novel triterpene derivatives, preparation thereof and use thereof |
| 04/07/2005 | CA2540151A1 Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders |
| 04/07/2005 | CA2540108A1 Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
| 04/07/2005 | CA2540083A1 Imidazopyridine-derivatives as inductible no-synthase inhibitors |
| 04/07/2005 | CA2540059A1 Controlled release formulations exhibiting an ascending rate of release |
| 04/07/2005 | CA2540056A1 Controlled release formulations of opioid and nonopioid analgesics |
| 04/07/2005 | CA2540050A1 Osmotic dosage forms for controlled delivery of alprazolam |
| 04/07/2005 | CA2540045A1 Dosage form for controlled release of an active agent formulation |
| 04/07/2005 | CA2540031A1 Macrocyclic inhibitors of hepatitis c virus ns3 serine protease |
| 04/07/2005 | CA2540021A1 Hcv inhibitors and methods of using them |
| 04/07/2005 | CA2540019A1 Quinazoline derivatives as antiproliferative agents |
| 04/07/2005 | CA2540008A1 Quinazoline derivatives |
| 04/07/2005 | CA2540005A1 Pulmonary disease treatment |
| 04/07/2005 | CA2539976A1 Therapeutic beta aminoacids |
| 04/07/2005 | CA2539961A1 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2] [2]- benzazepine, method for the production thereof and use thereof in the production of medicaments |
| 04/07/2005 | CA2539914A1 Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| 04/07/2005 | CA2539823A1 Hemiasterlin derivatives and uses thereof |
| 04/07/2005 | CA2539753A1 Treating neuropathic pain with neuropeptide ff receptor 2 agonists |
| 04/07/2005 | CA2539752A1 Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
| 04/07/2005 | CA2539731A1 Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases |
| 04/07/2005 | CA2539727A1 Bispecific oligonucleotide for the treatment of cns malignancies |
| 04/07/2005 | CA2539708A1 1,3-diaclyated,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof |
| 04/07/2005 | CA2539542A1 Delivery of therapeutic compounds via microparticles or microbubbles |
| 04/07/2005 | CA2539512A1 Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| 04/07/2005 | CA2539472A1 Ocular solutions containing a macrolide antibiotic and/or mycophenolic acid |
| 04/07/2005 | CA2539471A1 Carbamoyl-type benzofuran derivatives |
| 04/07/2005 | CA2539444A1 Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with nk1 antagonistic activity |
| 04/07/2005 | CA2539403A1 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| 04/07/2005 | CA2539252A1 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents |
| 04/07/2005 | CA2539250A1 Biphenyloxy-acids |
| 04/07/2005 | CA2539235A1 5-arylpyrimidines as anticancer agents |
| 04/07/2005 | CA2539234A1 ((((1h-indol-3yl) methylidene)amino)oxy)acetic acid derivatives and related compounds as pai-1 inhibitors for the treatment of inpairement of the fibrinolytic system and of thrombosis |
| 04/07/2005 | CA2539117A1 Inhibitors of histone deacetylase |
| 04/07/2005 | CA2539042A1 Gamma-secretase inhibitors |
| 04/07/2005 | CA2538711A1 Substituted heteroaryl benzofuran acids |
| 04/07/2005 | CA2538705A1 Ligands |
| 04/07/2005 | CA2538703A1 Substituted indole acid derivatives and their use as pai-1 inhibitors |
| 04/07/2005 | CA2538694A1 Heterocyclic- or aryloxy, -thio or -amino substituted indoles-2-carboxylic acids or esters as pai-1 |
| 04/07/2005 | CA2538671A1 Substituted oxadiazolidinediones als pai-1 inhibitors |
| 04/07/2005 | CA2538574A1 4-(1-benzofuran-3-yl-methylideneaminoxy.propoxy))-benzoic acid derivatives and related compounds as pai-1 inhibitors for the treatment of impairment of the fibrinolytic system andof thrombosis |
| 04/07/2005 | CA2538355A1 Substituted pyrrole-indoles as inhibitors of pai-1 |
| 04/07/2005 | CA2538353A1 Substituted oxadiazolidinediones as pai-1 inhibitors |
| 04/07/2005 | CA2538352A1 Methods and products which utilize n-acyl-l-aspartic acid |
| 04/07/2005 | CA2538263A1 Substituted sulfonamide-indole-2-carboxylic acid derivatives as pai-1 inhibitors |
| 04/07/2005 | CA2538259A1 4-(phenyl-ethylideneaminoxy-propoxy) -phenyl-acetic acid derivatives and related compounds as pai-1 inhibitors for the treatment of impairment of the fibrinolytic system and of thrombosis |
| 04/07/2005 | CA2538258A1 4- (1h-indol-3-yl-methylideneaminoxy-propoxy) -benzioc acid derivatives and related compounds as pai-1 inhibitors for the treatment of impairment of the fibrinolytic system and ofthrombisis |
| 04/07/2005 | CA2538215A1 Staple oligonucleotides and medicaments comprising the same |
| 04/07/2005 | CA2538037A1 Amino-substituted ethylamino .beta.2 adrenergic receptor agonists |
| 04/07/2005 | CA2538023A1 Therapeutic regimens for administering drug combinations |
| 04/07/2005 | CA2537874A1 Therapeutic agent for ageing macular degeneration |
| 04/07/2005 | CA2537812A1 C-met modulators and method of use |
| 04/07/2005 | CA2537520A1 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents |
| 04/07/2005 | CA2537004A1 Therapeutic agents useful for treating pain |
| 04/07/2005 | CA2536791A1 Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics |
| 04/07/2005 | CA2536402A1 Topical skin preparations for treatment of skin aging comprising a testosterone ester |
| 04/07/2005 | CA2533873A1 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation |